Hemay Pharmaceutical
Tianjin, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese biotech developing novel small molecule drugs for dermatological and oncological conditions with a patient-centered, cost-effective approach.
DermatologyOncology
Technology Platform
Focused on the discovery and development of novel small molecule therapeutics, with a patient-centered R&D system.
Opportunities
Large and growing Chinese dermatology (e.g., psoriasis) and oncology markets; differentiation through a focus on cost-effective therapeutics could drive adoption in China's price-sensitive healthcare system.
Risk Factors
Clinical trial failure risk for lead asset Mufemilast; intense competition in both dermatology (with numerous PDE4 and biologic competitors) and oncology; reliance on future financing to advance pipeline.
Competitive Landscape
In dermatology, faces competition from global PDE4 inhibitors like crisaborole and deucravacitinib, as well as biologics. In oncology, competes with numerous small molecule and biologic developers; differentiation may rely on novel targets or improved safety/efficacy profiles.